Last reviewed · How we verify
Desoximetasone 0.05% twice daily
Desoximetasone 0.05% twice daily is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Desoximetasone 0.05% twice daily |
|---|---|
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desoximetasone 0.05% twice daily CI brief — competitive landscape report
- Desoximetasone 0.05% twice daily updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI
Frequently asked questions about Desoximetasone 0.05% twice daily
What is Desoximetasone 0.05% twice daily?
Desoximetasone 0.05% twice daily is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc..
Who makes Desoximetasone 0.05% twice daily?
Desoximetasone 0.05% twice daily is developed by Sun Pharmaceutical Industries, Inc. (see full Sun Pharmaceutical Industries, Inc. pipeline at /company/sun-pharmaceutical-industries-inc).
What development phase is Desoximetasone 0.05% twice daily in?
Desoximetasone 0.05% twice daily is in Phase 2.